These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
176 related articles for article (PubMed ID: 18549465)
1. Screening differences and risk of cervical cancer in inflammatory bowel disease. Hutfless S; Fireman B; Kane S; Herrinton LJ Aliment Pharmacol Ther; 2008 Sep; 28(5):598-605. PubMed ID: 18549465 [TBL] [Abstract][Full Text] [Related]
2. Risk of cervical abnormalities in women with inflammatory bowel disease: a population-based nested case-control study. Singh H; Demers AA; Nugent Z; Mahmud SM; Kliewer EV; Bernstein CN Gastroenterology; 2009 Feb; 136(2):451-8. PubMed ID: 18996382 [TBL] [Abstract][Full Text] [Related]
3. Screening-preventable cervical cancer risks: evidence from a nationwide audit in Sweden. Andrae B; Kemetli L; Sparén P; Silfverdal L; Strander B; Ryd W; Dillner J; Törnberg S J Natl Cancer Inst; 2008 May; 100(9):622-9. PubMed ID: 18445828 [TBL] [Abstract][Full Text] [Related]
4. Cervical cancer screening in medically underserved California Latina and non-Latina women: effect of age and regularity of Pap testing. Howell LP; Gurusinghe S; Tabnak F; Sciortino S Cancer Detect Prev; 2009; 32(5-6):372-9. PubMed ID: 19264426 [TBL] [Abstract][Full Text] [Related]
5. Mortality by medication use among patients with inflammatory bowel disease, 1996-2003. Hutfless SM; Weng X; Liu L; Allison J; Herrinton LJ Gastroenterology; 2007 Dec; 133(6):1779-86. PubMed ID: 18054550 [TBL] [Abstract][Full Text] [Related]
6. A case-control study of the protective benefit of cervical screening against invasive cervical cancer in NSW women. Yang B; Morrell S; Zuo Y; Roder D; Tracey E; Jelfs P Cancer Causes Control; 2008 Aug; 19(6):569-76. PubMed ID: 18286380 [TBL] [Abstract][Full Text] [Related]
7. Clustering of inflammatory bowel disease with immune mediated diseases among members of a northern california-managed care organization. Weng X; Liu L; Barcellos LF; Allison JE; Herrinton LJ Am J Gastroenterol; 2007 Jul; 102(7):1429-35. PubMed ID: 17437504 [TBL] [Abstract][Full Text] [Related]
8. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Toruner M; Loftus EV; Harmsen WS; Zinsmeister AR; Orenstein R; Sandborn WJ; Colombel JF; Egan LJ Gastroenterology; 2008 Apr; 134(4):929-36. PubMed ID: 18294633 [TBL] [Abstract][Full Text] [Related]
9. Suboptimal rates of cervical testing among women with inflammatory bowel disease. Long MD; Porter CQ; Sandler RS; Kappelman MD Clin Gastroenterol Hepatol; 2009 May; 7(5):549-53. PubMed ID: 18996498 [TBL] [Abstract][Full Text] [Related]
10. Evaluation of cervical cancer screening program at a rural community of South Africa. Hoque M; Hoque E; Kader SB East Afr J Public Health; 2008 Aug; 5(2):111-6. PubMed ID: 19024420 [TBL] [Abstract][Full Text] [Related]
11. Does the use of 5-aminosalicylates in inflammatory bowel disease prevent the development of colorectal cancer? Bernstein CN; Blanchard JF; Metge C; Yogendran M Am J Gastroenterol; 2003 Dec; 98(12):2784-8. PubMed ID: 14687833 [TBL] [Abstract][Full Text] [Related]
12. Immunosuppression impairs response to pneumococcal polysaccharide vaccination in patients with inflammatory bowel disease. Melmed GY; Agarwal N; Frenck RW; Ippoliti AF; Ibanez P; Papadakis KA; Simpson P; Barolet-Garcia C; Ward J; Targan SR; Vasiliauskas EA Am J Gastroenterol; 2010 Jan; 105(1):148-54. PubMed ID: 19755964 [TBL] [Abstract][Full Text] [Related]
13. Relationship between clinical parameters and the colitis-colorectal cancer interval in a cohort of patients with colorectal cancer in inflammatory bowel disease. Brackmann S; Andersen SN; Aamodt G; Langmark F; Clausen OP; Aadland E; Fausa O; Rydning A; Vatn MH Scand J Gastroenterol; 2009; 44(1):46-55. PubMed ID: 18609187 [TBL] [Abstract][Full Text] [Related]